US BioShield II promise to be more attractive and less risky for industry participants
This article was originally published in Clinica
With bioterrorism preparedness one of the top Republican issues in Congress this year, members of the Senate health education labour and pensions (HELP) committee have begun work on legislation that would make it more attractive for companies to develop products designed to counter a biological attack.
You may also be interested in...
Australian patients with phototoxicity due to the rare condition EPP will now have their first treatment option – provided the drug's developer, Clinuvel, secures reimbursement under the Pharmaceutical Benefits Scheme.
Roche has partnered with Regeneron and Atea, but the company continues to leverage its long legacy in infectious diseases to identify good treatment options for the novel coronavirus.
Resilience has raised $800m to develop new technologies to manufacture complex drugs including vaccines, cell therapies and gene therapies.